Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fitusiran Prophylaxis in Pediatric Hemophilia A or B (ATLAS-KIDS)
NCT07285460Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Dec 2025
- Primary completion
- Aug 2029
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 12
01
Overview
A Phase 3 trial of fitusiran in hemophilia A, hemophilia B (HB), sponsored by Sanofi. Started Dec 2025; status: recruiting.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT07285460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285460.